WO2005077397A3 - Methods and compositions for treating vascular diseases - Google Patents

Methods and compositions for treating vascular diseases Download PDF

Info

Publication number
WO2005077397A3
WO2005077397A3 PCT/IB2005/000530 IB2005000530W WO2005077397A3 WO 2005077397 A3 WO2005077397 A3 WO 2005077397A3 IB 2005000530 W IB2005000530 W IB 2005000530W WO 2005077397 A3 WO2005077397 A3 WO 2005077397A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
vascular diseases
treating vascular
treating
Prior art date
Application number
PCT/IB2005/000530
Other languages
French (fr)
Other versions
WO2005077397A2 (en
Inventor
Ziad Mallat
Jean-Sebastien Silvestre
Alain Tedgui
Levy Bernard
Clotilde Thery
Sebastian Amigorena
Original Assignee
Inst Nat Sante Rech Med
Inst Curie
Univ Paris 7 Denis Diderot
Ziad Mallat
Jean-Sebastien Silvestre
Alain Tedgui
Levy Bernard
Clotilde Thery
Sebastian Amigorena
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Inst Curie, Univ Paris 7 Denis Diderot, Ziad Mallat, Jean-Sebastien Silvestre, Alain Tedgui, Levy Bernard, Clotilde Thery, Sebastian Amigorena filed Critical Inst Nat Sante Rech Med
Publication of WO2005077397A2 publication Critical patent/WO2005077397A2/en
Publication of WO2005077397A3 publication Critical patent/WO2005077397A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to methods and compositions for treating vascular diseases, and in particular ischemic diseases. More specifically, the present invention relates to the use of lactadherin or a variant thereof (or a coding nucleic acid), for treating ischemic conditions in a subject, particularly a human subject.
PCT/IB2005/000530 2004-02-12 2005-02-11 Methods and compositions for treating vascular diseases WO2005077397A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR0401403 2004-02-12
FR04/01403 2004-02-12
EP04292696 2004-11-15
EP04292696.4 2004-11-15

Publications (2)

Publication Number Publication Date
WO2005077397A2 WO2005077397A2 (en) 2005-08-25
WO2005077397A3 true WO2005077397A3 (en) 2006-04-13

Family

ID=34863123

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/000530 WO2005077397A2 (en) 2004-02-12 2005-02-11 Methods and compositions for treating vascular diseases

Country Status (1)

Country Link
WO (1) WO2005077397A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009064448A1 (en) 2007-11-15 2009-05-22 The Feinstein Institute For Medical Research Prevention and treatment of inflammation and organ injury after ischemia/reperfusion using mfg-e8
AU2012249539A1 (en) * 2011-04-28 2013-11-14 The Feinstein Institute For Medical Research MFG-E8 and uses thereof
WO2013139956A1 (en) * 2012-03-22 2013-09-26 Thrombogenics Nv Antibodies abrogating cell binding to lactadherin
WO2015025956A1 (en) * 2013-08-22 2015-02-26 国立大学法人九州大学 Pharmaceutical composition for treating myocardial damage, pharmaceutical composition for preventing myocardial damage, pharmaceutical composition for treating heart failure, pharmaceutical composition for preventing heart failure, method for treating or preventing myocardial damage or heart failure, mfg-e8, uses of mfg-e8, and method for screening compounds for treating or preventing myocardial damage or heart failure
CN113893328A (en) * 2017-06-14 2022-01-07 天津医科大学总医院 New application of human milk agglutinin subtype protein
CN111518191B (en) * 2020-04-27 2021-03-12 杭州璞湃科技有限公司 Milk agglutinin characteristic peptide and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000006723A1 (en) * 1998-07-30 2000-02-10 Yeda Research And Development Company Ltd At The Weizmann Institute Of Science Tumor associated antigen peptides and use of same as anti-tumor vaccines
FR2827872A1 (en) * 2001-07-30 2003-01-31 Roussy Inst Gustave In vitro preparation of membrane vesicles, useful for treatment of cancer and to induce immunological tolerance, from sample of mammalian body fluid
WO2003103700A1 (en) * 2002-06-07 2003-12-18 U.S. Department Of Veterans Affairs Method and composition for inhibing or slowing blood coagulation
WO2005005954A2 (en) * 2003-06-30 2005-01-20 The Brigham & Women's Hospital, Inc. Method, composition and kit for detecting phosphatidylserine (ps) on cell membranes

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000006723A1 (en) * 1998-07-30 2000-02-10 Yeda Research And Development Company Ltd At The Weizmann Institute Of Science Tumor associated antigen peptides and use of same as anti-tumor vaccines
FR2827872A1 (en) * 2001-07-30 2003-01-31 Roussy Inst Gustave In vitro preparation of membrane vesicles, useful for treatment of cancer and to induce immunological tolerance, from sample of mammalian body fluid
WO2003103700A1 (en) * 2002-06-07 2003-12-18 U.S. Department Of Veterans Affairs Method and composition for inhibing or slowing blood coagulation
WO2005005954A2 (en) * 2003-06-30 2005-01-20 The Brigham & Women's Hospital, Inc. Method, composition and kit for detecting phosphatidylserine (ps) on cell membranes

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BHATT DEEPAK L ET AL: "Antiplatelet and anticoagulant therapy in the secondary prevention of ischemic heart disease", CARDIOLOGY CLINICS, vol. 19, no. 2, May 2001 (2001-05-01), pages 253 - 265, XP009053269, ISSN: 0733-8651 *
HAEGGQVIST B ET AL: "MEDIN: AN INTEGRAL FRAGMENT OF AORTIC SMOOTH MUSCLE CELL-PRODUCED LACTADHERIN FORMS THE MOST COMMON HUMAN AMYLOID", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 96, no. 15, July 1999 (1999-07-01), pages 8669 - 8674, XP000919433, ISSN: 0027-8424 *
KUMAR C C: "INTEGRIN ALPHAVBETA3 AS A THERAPEUTIC TARGET FOR BLOCKING TUMOR-INDUCED ANGIOGENESIS", CURRENT DRUG TARGETS, BENTHAM SCIENCE PUBLISHER,, US, vol. 4, no. 2, February 2003 (2003-02-01), pages 123 - 131, XP009027835, ISSN: 1389-4501 *
PETERSON J A ET AL: "LACTABHERIN, A NOVEL CELL ADHESION MOLECULE AS A TARGET FOR RADIOIMMUNOTHERAPY OF BREAST CANCER", ANTICANCER RESEARCH, HELENIC ANTICANCER INSTITUTE, ATHENS,, GR, vol. 18, no. 5C, September 1998 (1998-09-01), pages 3871 - 3872, XP009036333, ISSN: 0250-7005 *
SHI JIALAN ET AL: "Lactadherin Inhibits Enzyme Complexes of Blood Coagulation by Competing for Phospholipid Binding Sites.", BLOOD, vol. 100, no. 11, 16 November 2002 (2002-11-16), & 44TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY; PHILADELPHIA, PA, USA; DECEMBER 06-10, 2002, pages Abstract No. 1002, XP002343235, ISSN: 0006-4971 *
SILVESTRE JEAN- SEBASTIEN ET AL: "Lactadherin promotes VEGF-dependent neovascularization", NATURE MEDICINE, vol. 11, no. 5, May 2005 (2005-05-01), pages 499 - 506, XP002356215, ISSN: 1078-8956 *
TAYLOR M R ET AL: "Lactadherin (formerly BA46), a membrane-associated glycoprotein expressed in human milk and breast carcinomas, promotes Arg-Gly-Asp (RGD)-dependent cell adhesion", DNA AND CELL BIOLOGY, NEW YORK, NY, US, vol. 16, no. 7, July 1997 (1997-07-01), pages 861 - 869, XP002102000, ISSN: 1044-5498 *

Also Published As

Publication number Publication date
WO2005077397A2 (en) 2005-08-25

Similar Documents

Publication Publication Date Title
WO2006067122A3 (en) Binding molecules capable of neutralizing west nile virus and uses thereof
WO2004092215A3 (en) Methods of treatment of inflammatory diseases using specific binding agents of human angiopoietin-2
WO2007141274A3 (en) Human binding molecules having killing activity against staphylococci and uses thereof
WO2007090569A8 (en) Conditioned blood composition and method for its production
WO2008104306A3 (en) Substituted 4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof
WO2005079363A3 (en) Aptamer therapeutics useful in the treatment of complement-related disorders
IL179445A0 (en) 1-methyl-3-trifluoromethyl-pyrazole-4-carboxylic acid (ortho-phenyl)-anilides and use thereof as fungicide
IL187982A0 (en) Human placental collagen compositions, processes for their preparation, methods of their use and kits comprising the compositions
WO2007095316A3 (en) Compositions and methods for oligonucleotide formulations
WO2006003388A8 (en) Compositions and methods for treating inflammatory disorders
WO2007022518A3 (en) New uses of glucoregulatory proteins
WO2006003492A3 (en) Compositions and methods for treating pathological infections
WO2006068729A3 (en) Methods and compositions for enhancing iron absorption
WO2005097175A3 (en) Human glp-1 mimetibodies, compositions, methods and uses
WO2006088888A3 (en) Aptamer therapeutics useful in the treatment of complement-related disorders
WO2006102061A3 (en) Methods of decreasing calcification
WO2008088524A3 (en) Thrombospondin-domain-deficient r-spondin 1 protein as gastrointestinal tract epithelial proliferation factor
WO2005077397A3 (en) Methods and compositions for treating vascular diseases
EP1765331A4 (en) Methods and compositions for the treatment of pulmonary diseases
WO2006024958A3 (en) Cannabinoid compositions and methods of use thereof
EP1740221A4 (en) Methods and compositions for the treatment of polycystic diseases
WO2010000851A3 (en) Methods for modulating angiogenesis via dystrophin dp71
WO2007022642A3 (en) Anti-inflammatory molecules and their uses
WO2006043060A3 (en) Mam domain containing protein
WO2005037219A3 (en) Disinfecting teat care compositions

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase